Education
About Us
Working with TipRanks
Follow Us
Tenax Therapeutics (TENX)
NASDAQ:TENX
TENX Stock Chart & Stats
$14.01
<$0.01(0.16%)
At close: 4:00 PM EST
$14.01
<$0.01(0.16%)
Day’s Range― - ―
52-Week Range$4.63 - $18.38
Previous CloseN/A
Volume25.45K
Average Volume (3M)285.76K
Market Cap
$87.47M
Enterprise Value-$38.37M
Total Cash (Recent Filing)$99.37M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Mar 26, 2026EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding6,243,575
10 Day Avg. Volume386,168
30 Day Avg. Volume285,761
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.03
Price to Sales (P/S)0.00
P/FCF Ratio-6.38
Enterprise Value/Market Cap-0.44
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.89
Forecast
1Y Price Target
$25.00Price Target Upside78.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Patent ProtectionAn intention from the European Patent Office to grant coverage for levosimendan use in PH‑HFpEF would extend intellectual property protection and strengthen the therapy’s commercial positioning.
Patient‑reported Symptom ImprovementAnecdotal reports from the open‑label extension indicate patients report marked symptomatic improvement after re‑initiation on oral levosimendan, suggesting potential quality‑of‑life benefits.
Trial Design And Statistical IntegrityThe Phase III LEVEL trial remains highly powered to detect the planned treatment effect and a prespecified blinded sample‑size reassessment was conducted without unblinding, reinforcing the study’s statistical integrity.
Bears Say
Regulatory Scrutiny RiskRegulators may view unblinded or subjective evidence skeptically, potentially increasing the need for additional controlled data before granting approval.
Reliance On Anecdotal EvidenceDependence on anecdotal improvements from the open‑label extension may not translate into objective improvements on blinded clinical endpoints required for regulatory decisions.
Unblinded Study BiasPlacebo effects in unblinded settings create the risk that observed improvements reflect bias rather than true drug efficacy, complicating interpretation of results.
Tenax Therapeutics News
TENX FAQ
What was Tenax Therapeutics’s price range in the past 12 months?
Tenax Therapeutics lowest stock price was $4.63 and its highest was $18.38 in the past 12 months.
What is Tenax Therapeutics’s market cap?
Tenax Therapeutics’s market cap is $87.47M.
When is Tenax Therapeutics’s upcoming earnings report date?
Tenax Therapeutics’s upcoming earnings report date is Mar 26, 2026 which is in 55 days.
How were Tenax Therapeutics’s earnings last quarter?
Tenax Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.312 by -$0.088.
Is Tenax Therapeutics overvalued?
According to Wall Street analysts Tenax Therapeutics’s price is currently Undervalued.
Does Tenax Therapeutics pay dividends?
Tenax Therapeutics does not currently pay dividends.
What is Tenax Therapeutics’s EPS estimate?
Tenax Therapeutics’s EPS estimate is -0.41.
How many shares outstanding does Tenax Therapeutics have?
Tenax Therapeutics has 6,243,575 shares outstanding.
What happened to Tenax Therapeutics’s price movement after its last earnings report?
Tenax Therapeutics reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.312. Following the earnings report the stock price went down -4.292%.
Which hedge fund is a major shareholder of Tenax Therapeutics?
Currently, no hedge funds are holding shares in TENX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tenax Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.00 (78.44% Upside)
$25.00 (78.44% Upside)
Blogger Sentiment
Bullish
TENX Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $189.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 58.2%
Last 30 Days ▲ 58.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
125.60%
12-Months-Change
Fundamentals
Return on Equity
-44.80%
Trailing 12-Months
Asset Growth
3.03%
Trailing 12-Months
Company Description
Tenax Therapeutics
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
TENX Stock 12 Month Forecast
Average Price Target
$25.00
▲(78.44% Upside)
Technical Analysis
Tempest Therapeutics
―
Relmada Therapeutics
―
VYNE Therapeutics
―
Longeveron
―
Calidi Biotherapeutics
―
Ownership Overview
0.51% Insiders
2.83% Mutual Funds
<0.01% Other Institutional Investors
93.20% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---